Human epidermal growth factor receptor 2 (HER2)

Where the papers sit

64 papers from the last 6 months study Human epidermal growth factor receptor 2 (HER2) directly · updated from PubMed 8 Oct 2026

• HER2-Targeted Therapeutic Platforms

  HER2 expression is being converted into treatment and diagnostic opportunities across solid tumours. Trispecific T-cell engagers, CAR-T cells, bispecific engagers, antibody-drug conjugates and phototherapy aim to overcome heterogeneity or improve tumour penetration. Radiomics, immunohistochemistry and molecular profiling are refining HER2 assessment in cancers beyond breast disease. The evidence remains heterogeneous, spanning early clinical studies, engineered constructs and exploratory biomarker work.

  17 papers · 26.6%

• Antibody-Based HER2 Therapies

  Antibody engineering is moving HER2 treatment beyond conventional trastuzumab toward site-specific ADCs, bispecific antibodies, radioconjugates and mRNA-LNP delivery. Zanidatamab combinations and macrophage-activating bispecifics seek to strengthen immune-mediated tumour control. Radionuclide conjugates are being developed for metastatic and trastuzumab-resistant disease, while vaccines and DNA nanocomplexes combine HER2 suppression with immune activation. Pharmacokinetics, payload placement and immune contexture remain major design constraints.

  14 papers · 21.9%

• HER2-Positive Breast Cancer Care

  HER2 stratification is broadening from amplified disease to HER2-low and HER2-zero metastatic breast cancer. Neoadjuvant response, survival, brain metastases and discordant tumour–axillary pathology remain central clinical questions. Tucatinib, trastuzumab-based radionuclide therapy and precision HER2 targeting are being evaluated for advanced and treatment-resistant disease. Testing practices and real-world treatment selection remain uneven.

  13 papers · 20.3%

• HER2-Driven Lung Cancer

  HER2-mutant or amplified NSCLC is being treated with targeted kinase inhibition, including pyrotinib plus apatinib and later-line TKIs. Progression-free survival and gastrointestinal toxicity, especially diarrhea, recur as key outcomes. Molecular profiling is exposing coexisting alterations such as EGFR L858R and HER2 amplification that complicate treatment selection. ADCs are emerging as another option, although evidence remains early and includes limited SCLC data.

  6 papers · 9.4%

• Nucleic Acid HER2 Technologies

  Nucleic-acid platforms are being adapted for intracellular antisense delivery, HER2-directed payload transport and highly sensitive diagnostics. Spherical nucleic acids, peptide nucleic acids, aptasensors and CRISPR/Cas12a systems emphasize nuclease protection, spatial precision and signal amplification. Several approaches aim to detect HER2 directly in living cells or clinical specimens rather than rely only on tissue assays. Translation still depends on limiting systemic toxicity and improving delivery specificity.

  5 papers · 7.8%

• Others — Receptor-Targeted Cancer Biology

  Receptor biology spans EGFR, FGFR2, hormone receptors and HER2 across breast, biliary, colorectal and ovarian cancers. The work ranges from resistance mutations and prognostic subtypes to CAR-T redirection, degraders and oncolytic-virus combinations. Multi-target small molecules and immune-engineering platforms recur, but no single disease, mechanism or therapeutic direction dominates. The common ground is broad investigation of receptor-guided cancer treatment and classification.

  9 papers · 14.1%